Inogen board member Kristen Miranda resigns; Tom West appointed effective April 1, 2023

Inogen Inc

Kristen Miranda resigned as director effective March 31, 2023; not due to any disagreement with the company.
Thomas A. West appointed to Board effective April 1, 2023; will serve as Class III director and on Nominating/Governance and Compliance Committees.
West is President and CEO of Nalu Medical; previously CEO of Intersect ENT and held senior roles at Hologic and Johnson & Johnson.
West receives annual cash fees of $45,000 for Board service and $5,000 per committee, plus initial RSU award of 1,712 shares vesting by June 8, 2023.
Appointment expands board expertise in medtech and operational leadership as Inogen pursues growth transformation.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Thomas A. West

Director

INGN · Inogen Inc

Effective: 2023-04-01
Filed: March 22, 2023, 7:59 PM ET

On March 21, 2023, the Board, upon recommendation of the Nominating and Governance Committee, appointed Thomas A. West to the Board, effective April 1, 2023.

Departed

Kristen Miranda

Director

INGN · Inogen Inc

Effective: 2023-03-31
Filed: March 22, 2023, 7:59 PM ET

On March 19, 2023, Kristen Miranda notified Inogen, Inc. (“the Company”) of her resignation as a member of the Board of Directors (the “Board”) of the Company, the Compliance Committee of the Board (the “Compliance Committee”), and the Nominating and Governance Committee of the Board (the “Nominating and Governance Committee”), in each case effective as of March 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Thomas A. West was appointed as Director at Inogen Inc.

Action: appointed
Role: Director

Exact text from the filing

On March 21, 2023, the Board, upon recommendation of the Nominating and Governance Committee, appointed Thomas A. West to the Board, effective April 1, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Kristen Miranda resigned as Director at Inogen Inc.

Action: resigned
Role: Director

Exact text from the filing

On March 19, 2023, Kristen Miranda notified Inogen, Inc. (“the Company”) of her resignation as a member of the Board of Directors (the “Board”) of the Company, the Compliance Committee of the Board (the “Compliance Committee”), and the Nominating and Governance Committee of the Board (the “Nominating and Governance Committee”), in each case effective as of March 31, 2023.

View on SEC.gov

Inogen Inc filing history →

Source: SEC EDGAR

accession 0000950170-23-009177

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.